In May 2018, the General Assembly of the Rare Disease Action Forum (RDAF) elected the Forum’s board, welcoming two new board members: Ms. Rea Lal, Rare Disease Lead at Pfizer in Switzerland, and Dr. Jacqueline de Sá, General Secretary of the Swiss umbrella patient organization ProRaris. Rea Lal succeeds Dr. Roland Rutschmann, CEO at Curatis who did not run for reelection. The secretariat would like to thank Dr. Roland Rutschmann for the considerable expertise and great contributions he made as a board member since the founding of the RDAF. The new board composition reaffirms the multistakeholder approach of the Forum. The RDAF is looking forward to continuing its efforts to facilitate the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.
Internationaler Tag der Seltenen Krankheiten 2026: Gemeinsam Fortschritte stärken und die Versorgung nachhaltig verbessern
Am heutigen Internationalen Tag der Seltenen Krankheiten erinnert das Rare Disease Action Forum (RDAF) daran, dass über 500'000 Menschen in der Schweiz von einer seltenen Erkrankung betroffen sind, viele von ihnen weiterhin ohne gesicherten Zugang zu Diagnose,...